Data from Rebiotix's Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016

ROSEVILLE, Minn., Oct. 17, 2016 /PRNewswire/ -- Rebiotix Inc., a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that data from its Phase 2b, randomized, double-blind, placebo-controlled trial of RBX2660 as a possible prevention of recurrent Clostridium difficile (C.diff.) infection after a standard of care course of antibiotics (PUNCH™ CD2) will be presented at the United European Gastroenterology (UEG) Week 2016, to be held October 15-19 in Vienna, Austria.

The late-breaking oral presentation, "RBX2660, a microbiota-based drug for the prevention of recurrent Clostridium difficile infection, is safe and effective: results from a randomised, double-blinded, placebo-controlled trial," (Abstract #LB08) will be presented by Robert Orenstein, D.O., an Associate Professor of Medicine and the Chair of the Division of Infectious Diseases at Mayo Clinic in Arizona, and study investigator on Monday, October 17, 2016, at 3:45-3:57 pm CET.

Additionally, data from the PUNCH™ CD2 clinical trial will be the subject of three poster presentations at American College of Gastroenterology (ACG) 2016 to be held October 14-19, 2016 in Las Vegas, Nevada:

• "Does the Donor Matter? Results from PUNCH CD 2: A Randomized Controlled Trial of a Microbiota-based Drug for Recurrent Clostridium difficile Infection," Program Number P109, Sunday October 16, 2016, 3:30-7:00 pm, PT
• "Placebo Response in a Randomized Controlled Trial of a Microbiota-based Drug Targeted at Recurrent C. difficile Infection: Results of the PUNCH CD 2 Trial," Program Number P872, Monday, October 17, 2016, 10:30 am – 4:00 pm, PT
• "Durable Prevention of Recurrent C. difficile Infection with RBX2660: Results of the PUNCH CD 2 Trial," Program Number P1633, Tuesday, October 18, 2016, 10:30 am – 4:00 pm, PT

Lee Jones, co-founder, president and CEO, commented, "We are excited for the opportunity to have data from our Phase 2b clinical trial of RBX2660 presented at UEG Week 2016 and ACG 2016, two of the preeminent gastroenterology conferences in the world. Based on the results of the PUNCH™ CD2 study, our plan is to advance the clinical development of RBX2660 into a Phase 3 trial in recurrent C.diff. with the ultimate goal of bringing to market a drug product that addresses this critically important and potentially life-threatening disease."

About Rebiotix Inc.
Rebiotix Inc. is a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its Phase 3-ready drug candidate, RBX2660, having successfully completed a Phase 2b randomized, double-blind, placebo-controlled trial as a possible prevention of recurrent  Clostridium difficile (C.diff.) infection after a standard of care course of antibiotics (PUNCH™ CD2). RBX2660 has been granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA  for its potential to treat recurrent C.diff. infection. Rebiotix's development pipeline includes multiple formulations targeting several disease indications and is built around its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient's intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

Rebiotix Media Contact:
Amy Wheeler
Tiberend Strategic Advisors
646-362-5750
[email protected]

SOURCE Rebiotix Inc.